Chemotherapy Shortly Before COVID-19 Diagnosis Increases Risk of Death in Patients with Certain Cancers
In patients with lung and other thoracic cancers, prior treatment with chemotherapy was associated with an increased risk of death in those diagnosed with COVID-19, according to data presented at the 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program.
Data from the Thoracic cancERs international coVid 19 cOLlaboraTion (TERAVOLT) registry found that only patients receiving chemotherapy treatment within 3 months of COVID-19 diagnosis had a significantly increased risk of dying from the virus compared with patients not receiving chemotherapy.
“A number of factors — pre-existing lung damage, smoking status, advanced age, and comorbidities — make patients with thoracic cancers especially vulnerable to COVID-19. There are a lot of questions right now, and not a lot of answers. These findings give us some insights into outcomes for patients with cancer who develop COVID-19,” said ASCO President Howard A. Burris III, MD, FACP, FASCO in a press release.
Horn L. Thoracic Cancers International COVID-19 Collaboration (TERAVOLT): Impact of type of cancer therapy and COVID therapy on survival. Presented at: 2020 American Society of Clinical Oncology (ASCO) Virtual Scientific Program; May 29-31.